Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

WSC 2023 | Neuroprotection in conjunction with EVT in acute ischemic stroke

Adnan Qureshi, MD, University of Missouri-Columbia, Columbia, MO, discusses the use of neuroprotective agents in conjunction with endovascular thrombectomy (EVT) for the treatment of acute ischemic stroke. Neuroprotective agents have a long history of success in preliminary experimental models, which has not translated into clinical trial success, perhaps due to a lack of blood flow to deliver the molecule to the affected regions. EVT, which enables recanalization and the restoration of blood flow, offers the potential for delivering neuroprotective agents to enhance outcomes. However, there is a narrow time frame after stroke symptom onset in which neuroprotective molecules may be effective, potentially necessitating administration before EVT in a pre-hospital setting. Dr Qureshi emphasizes that, whilst recanalization with EVT has been the main focus for many years, it’s essential to consider various other factors to optimize favorable outcomes. This interview took place at the World Stroke Congress (WSC) 2023 in Toronto, Canada.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


Adnan Qureshi reports the following disclosures: I am founder or cofounder of Qureshi Medical, QuReVasc, and DyQure.